Persistence of BCR/ABL mRNA-Expressing Bone-Marrow Cells in Patients with Chronic Myelogenous Leukemia in Complete Cytogenetic Remission Induced by Interferon-alpha Therapy

References

• Kurzrock R., Gutterman J., Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. NEIM 1988; 319: 990–998
   PubMed Web of Science ®Google Scholar
• McGlave P. Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Sem. Hematol 1990; 27: 23–30
   PubMed Web of Science ®Google Scholar
• Bertheas M. F., Lafage M., Levy P., Blaise D., Stoppa A., Viens P., Mannoni P., Maraninchi D. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood 1991; 78: 3103–3106
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Gluckman E., Blaise D., Guyotat D., Rio B., Pico J. L., Leblond V., Michallet M., Dreyfus Ifrah N., Bordigoni A. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukemias. The Lancet 1987; 2: 175–178
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J., Gutterman J. Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann. Intern. Med 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• Morra E., Lazzarino M., Alimena G., Liberati A., Grignani F., Mandelli F., Bernasconi C. The role of interferon in the treatment of chronic myelogenous leukemia results and prospects. Leukemia & Lymphoma 1992; 6: 305–315
   Web of Science ®Google Scholar
• Arcese W., Mauro F. R., Screnci M. Alimena, Alimena G., Iori A. P., De Cuia M., Lo Coca F., Montefusco E., Fazi P., Mandelli F. Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation. European J. Haematol 1990; 45: 36–39, Suppl 52
   PubMed Web of Science ®Google Scholar
• Gabert J., Thuret I., Lafage M., Carcassonne Y., Maraninchi D., Mannoni P. Detection of residual ber/abl translocation by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation. The Lancet 1989; 2: 1225–1228
   Google Scholar
• Chirgwin J., Przybyla A., MacDonald R., Rutter W. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochem 1979; 18: 5294–5299
   PubMed Web of Science ®Google Scholar
• Kawasaki E. S., Clark S. S., Coyne M. Y., Smith S. D., Champlin R., Witte O. N., McCormick F. P. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc. Natl. Acad. Sci. USA 1988; 85: 5698–5702
   PubMed Web of Science ®Google Scholar
• Kwok S., Higushi R. Avoiding false positive with PCR. Nature 1989; 339: 237–238
   PubMed Web of Science ®Google Scholar
• Martiat P., Maisin D., Philippe M., Ferrant A., Michaux J. L., Cassiman J. J., Van den Berghe H., Sokal G. Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers. Br. J. Haematol 1990; 75: 355–358
   PubMed Web of Science ®Google Scholar
• Dhingra K., Kurzrock R., Kantarjian H., Baine R., Eastman P. S., Ku S., Gutterman J. U., Talpaz M. Minimal residual disease in interferon-treated chronic myelogenous leukemia results and pitfalls of analysis based on polymerase chain reaction. Leukemia 1992; 6: 754–760
   PubMed Web of Science ®Google Scholar
• Bilhou-Nabera C., Vard F., Marit G., Gharbi M., Salzes S., Reiffers J., Broustet A., Bernard P. Complete cytogenetíc conversion in chronic myelocytic leukemia patients undergoing interferon à therapy follow-up with reverse polymerase chain reaction. Leukemia 1992; 6: 595–598
   PubMed Web of Science ®Google Scholar
• Opalka B., Wandl U. B., Becher R., Kloke O., Nagel-Hiemke M., Maritz T., Beer L., Seeber S., Niederle N. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha 2b alone or in combination with interferon gamma. Blood 1991; 78: 2188–2193
   PubMed Web of Science ®Google Scholar
• Snyder D., Rossi J., Wang J., Sniecinski I., Slovak M., Wallace R., Forman S. Persistence of ber-abl gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Transplantation 1991; 51: 1033–1040
   PubMed Web of Science ®Google Scholar
• Lin F., Goldman J. M., Cross N. C. P. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. B. J. Haematol 1994; 86: 683–685
   PubMed Web of Science ®Google Scholar
• Miyamura K., Tahara T., Tanimoto M., Morishita Y., Kawashima K., Morishima Y., Saito H., Tsuzuki S., Takeyama K., Kodera Y., Matsuyama K., Hirabayashi N., Yamada H., Naito K., Imai K., Sakamaki H., Asai O., Mizutani S. Long persistent ber-abl positive transcript detected by polymerase chain reaction after bone marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. Blood 1993; 81: 1089–1093
   PubMed Web of Science ®Google Scholar
• Guerrasio A., Martinelli G., Saglio G., Rosso C., Zaccaria A., Rosti G., Testoni N., Ambrosetti A., Izzi T., Sessarego M., Frassoni F., Gasparini P., Chiamenti A., Di Bartolomeo P., Pignatti P. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants. Leukemia 1992; 6: 507–512
   PubMed Web of Science ®Google Scholar
• Hughes T. P., Morgan G. J., Martial P., Goldman J. M. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874–878
   PubMed Web of Science ®Google Scholar
• Lee M. S., Kantarjian H., Talpaz M., Freireich E. J., Deisseroth A., Trujillo J. M., Stass S. A. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 1992; 79: 1920–1923
   PubMed Web of Science ®Google Scholar
• Lion T., Izraeli S., Henn T., Gaiger A., Mor W., Gadner H. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992; 6: 495–499
   PubMed Web of Science ®Google Scholar
• Malinge M., Mahon F., Delfau M., Daheron L., Kitzis A., Guilhot F., Tanzer J., Grandchamp B. Quantitative determination of the hybrid ber-abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br. J. Haematol 1992; 82: 701–707
   PubMed Web of Science ®Google Scholar
• Zhao L., Kantarjian H. M., Van Oort J., Trujillo J. M., Liang J. C. Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment. Leukemia 1993; 7: 168–171
   PubMed Web of Science ®Google Scholar
• Dewald G. W., Schald C. R., Christensen E. R., Tiede A. L., Zinsmeister A. R., Spurbeck J. L., Thibodeau S. N., Jalai S. M. The application of fluorescent in situ hybridization to detect Mber/abl fusion in variant Ph chromosomes in CML and ALL. Cancer Gen. Cytogen 1993; 71: 7–14
   PubMed Web of Science ®Google Scholar
• Keating A., Wang X. H. Variable expression of ber-abl and ber gene mRNA in hematopoietic colonies from Ph(+) chronic myeloid leukemia. Exp. Hematol 1991; 1991, 539
   Google Scholar
• Coulombel L., Kalousek D. K., Eaves C. J., Gupta C. M., Eaves A. C. Long-term bone marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Phl chromosome positive chronic myeloid leukemia. NEJM 1983; 308: 1493–1498
   PubMed Web of Science ®Google Scholar
• Verfaillie C. M., Miller W. J., Boylan K., McGlave P. B. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003–1010
   PubMed Web of Science ®Google Scholar
• Leemhuis T., Leibowitz D., Cox G., Silver R., Srour E. F., Tricot G., Hoffman R. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 1993; 81: 801–807
   PubMed Web of Science ®Google Scholar
• Barnett M. J., Eaves C. J., Phillips G. L., Kalousek D. K., Klingemann H. G., Lansdorp P. M., Reece D. E., Shepherd J. D., Shaw G. J., Eaves A. C. Successful autografting in chronic myeloid leukemia after maintenance in culture. Bone Marrow Trans 1989; 4: 345–351
   PubMed Web of Science ®Google Scholar
• Keating A., Jamieson C., Hornby A., Wang X. H., Levy J. Photodynamic elimination of clonogenic Ph+ chronic myeloid leukemia cells. Leukemia & Lymphoma 1993; 11: 265–269, Suppl 1
   PubMed Web of Science ®Google Scholar
• Stoppa A. M., Maraninchi D., Lafage M., Mannoni P., Novakovitch G., Blaise D., Gaspard M. H., Michel G., Carcassone Y. Liquid culture and cryopreservation of marrow cells of leukemic patients prior to autologous bone marrow transplantation. B. J. Haematol 1989; 72: 519–523
   PubMed Web of Science ®Google Scholar
• Dunbar C. E., Stewart F. M. Separating the wheat from the chaff: selection of benign hematopoietic cells in chronic myeloid leukemia. Blood 1992; 79: 1107–1110
   PubMed Web of Science ®Google Scholar